Key Points
- Altimmune CEO Jerome Benedict Durso bought 20,000 shares on March 6 at an average price of $3.54 for $70,800, increasing his stake to 32,500 shares — a 160% rise in his ownership.
- Altimmune recently missed quarterly EPS expectations (reported -$0.27 vs. -$0.25), posted only $0.03M in revenue and negative margins, while analysts hold a consensus rating of Hold with an average target price of $16.60.
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory Weaver purchased 5,000 shares of the business's stock in a transaction on Friday, March 6th. The shares were acquired at an average price of $3.54 per share, with a total value of $17,700.00. Following the purchase, the chief financial officer owned 28,078 shares of the company's stock, valued at approximately $99,396.12. This trade represents a 21.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Altimmune Trading Up 9.6%
ALT stock opened at $3.88 on Tuesday. Altimmune, Inc. has a 1-year low of $2.90 and a 1-year high of $7.73. The firm has a market cap of $437.78 million, a P/E ratio of -3.84 and a beta of 0.13. The business's 50 day moving average is $4.49 and its 200-day moving average is $4.29. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08.
Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. Equities analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. lifted its position in Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company's stock valued at $32,000 after purchasing an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after buying an additional 2,241 shares during the period. Concurrent Investment Advisors LLC raised its stake in shares of Altimmune by 10.4% during the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company's stock worth $96,000 after buying an additional 2,500 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Altimmune by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company's stock worth $108,000 after buying an additional 2,748 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in Altimmune by 4.0% in the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company's stock valued at $289,000 after buying an additional 3,047 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have issued reports on ALT. Citigroup reissued a "market outperform" rating on shares of Altimmune in a report on Wednesday, November 12th. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Thursday. B. Riley Financial dropped their target price on shares of Altimmune from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Friday. Barclays started coverage on shares of Altimmune in a report on Tuesday, January 27th. They set an "overweight" rating and a $20.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Altimmune in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Altimmune has an average rating of "Hold" and a consensus target price of $16.60.
Read Our Latest Report on Altimmune
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
